目的 研究燈臺(tái)葉顆粒聯(lián)合孟魯司特鈉片治療小兒遷延性肺炎的臨床療效。方法 選取2018年10月—2019年10月在河南省兒童醫(yī)院治療的120例遷延性肺炎患兒，將所有患兒隨機(jī)分為對(duì)照組和治療組，每組各60例。對(duì)照組患兒口服孟魯司特鈉片，5 mg/次，1次/d。治療組在對(duì)照組治療的基礎(chǔ)上口服燈臺(tái)葉顆粒，10 g/次，3次/d。兩組患兒持續(xù)治療10 d。觀察兩組的臨床療效，比較兩組的復(fù)發(fā)情況、臨床癥狀好轉(zhuǎn)時(shí)間、肺功能指標(biāo)、血清炎性指標(biāo)。結(jié)果 治療后，治療組總有效率（96.67%）顯著高于對(duì)照組（83.33%）（P<0.05），治療組復(fù)發(fā)率（1.67%）顯著低于對(duì)照組（13.33%）（P<0.05）。治療后，治療組患兒退熱時(shí)間、止咳時(shí)間、肺部濕啰音消失時(shí)間明顯短于對(duì)照組（P<0.05）。治療后，兩組患兒一秒用力呼氣量（FEV1）、用力肺活量（FVC）、FEV1/FVC顯著升高（P<0.05），且治療組肺功能指標(biāo)升高較多（P<0.05）。治療后，兩組患兒血清C-反應(yīng)蛋白（CRP）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）水平顯著降低（P<0.05）；并且治療組血清炎性指標(biāo)水平降低較多（P<0.05）。結(jié)論 燈臺(tái)葉顆粒聯(lián)合孟魯司特鈉片治療小兒遷延性肺炎具有較好的臨床療效，能夠改善患兒肺功能，降低血清炎癥指標(biāo)水平，值得在臨床上推廣應(yīng)用。

Objective To study the curative effect of Dengtaiye Granules combined with Montelukast Sodium Tablets in treatment of children’s persistent pneumonia. Methods Children (120 cases) with persistent pneumonia in Henan Children’s Hospital from October 2018 to October 2019 were randomly divided into control and treatment groups, and each group had 60 cases. Children in the control group were po administered with Montelukast Sodium Tablets, 5 mg/time, once daily. Children in the treatment group were po administered with Dengtaiye Granules on the basis of the control group, 10 g/time, three times daily. Children in two groups were treated for 10 d. After treatment, the clinical efficacies were evaluated, and recurrence rates, clinical symptom relief times, pulmonary function indexes, serum levels of inflammatory indexes in two groups were compared. Results After treatment, the total effective rate of the treatment group (96.67%) was significantly higher than that of the control group (83.33%) (P<0.05), and the recurrence rate of the treatment group (1.67%) was significantly lower than that of the control group (13.33%) (P<0.05). After treatment, the antipyretic time, antitussive time, and disappearance time of lung wet rales in the treatment group were significantly shorter than those in the control group (P<0.05). After treatment, FEV1, FVC, and FEV1/FVC in two groups were significantly increased (P<0.05), and the pulmonary function indexes in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of CRP, TNF-α, and IL-6 in the two groups were significantly decreased (P<0.05). After treatment, the serum levels of inflammatory indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Dengtaiye Granules combined with Montelukast Sodium Tablets has clinical curative effect in treatment of children’s persistent pneumonia, can improve the lung function of children and reduce the serum level of inflammation indexes, which is worthy of clinical application.

R974